NanoViricides Reports Safety Profile Of Its First Drug Candidate In Dermal Treatment Study; Drug Has Successfully Completed First Of Safety/Toxicology Studies Moving Towards Clinical Trials, Was Well Tolerated In Animals
Benzinga Newsdesk